FLOW CYTOMETRY, CD 61

The Flow Cytometry CD61 Test is a specialized immunophenotyping assay used to detect and measure the expression of CD61, also known as Integrin Beta-3 (GPIIIa). CD61 is primarily expressed on platelets, megakaryocytes, and megakaryocytic precursor cells, making it an important marker for evaluating megakaryocytic lineage and related hematological disorders.

Flow cytometry technology enables rapid analysis of thousands of cells individually, allowing accurate identification of CD61-positive cell populations. CD61 is commonly included in specialized flow cytometry panels used for diagnosing Acute Megakaryoblastic Leukemia (AMKL), evaluating platelet-related disorders, and assessing bone marrow abnormalities.

Because CD61 is strongly associated with megakaryocyte development and platelet formation, it is particularly useful for determining whether abnormal blast cells originate from the megakaryocytic lineage. The marker also contributes valuable information when differentiating specific subtypes of acute leukemia.

Benefits of the Test

• Identifies megakaryocytic cell populations
• Assists in leukemia classification
• Helps evaluate bone marrow disorders
• Supports assessment of platelet-related abnormalities
• Assists in disease monitoring and follow-up
• Provides valuable immunophenotypic information

Why Doctors Recommend This Test

Doctors may recommend Flow Cytometry CD61 testing for:

• Suspected Acute Megakaryoblastic Leukemia (AMKL)
• Acute leukemia immunophenotyping
• Bone marrow disorder evaluation
• Investigation of abnormal blast cells
• Platelet production abnormalities
• Myeloproliferative disorder assessment
• Hematological malignancy workup
• Comprehensive flow cytometry analysis

The test helps determine megakaryocytic differentiation and contributes to accurate disease classification.

Preparation Before Test

The test may require:

• Bone marrow aspirate
• Peripheral blood sample
• Other clinically relevant specimens

Preparation generally includes:

• No fasting is required
• Inform your physician about current medications
• Follow laboratory collection instructions

The sample is analyzed using advanced multiparameter flow cytometry techniques.

Normal Reporting Time

Results are generally available within 1 to 3 working days, depending on laboratory workflow and panel complexity.

Who Should Take This Test?

• Patients with suspected acute leukemia
• Individuals undergoing bone marrow evaluation
• Patients with abnormal blood counts
• Individuals with suspected megakaryocytic disorders
• Patients requiring leukemia immunophenotyping
• Individuals referred by hematologists or oncologists

Flow Cytometry CD61 testing is an important component of specialized hematological diagnostics and leukemia classification.

Clinical Significance

CD61 expression may be associated with:

• Acute Megakaryoblastic Leukemia (AMKL)
• Megakaryocytic Blast Populations
• Platelets
• Megakaryocytes
• Myeloproliferative Disorders
• Bone Marrow Disorders
• Platelet Production Abnormalities

Detection of CD61-positive blast cells may support the diagnosis of megakaryocytic leukemia and help determine cell lineage during leukemia evaluation.

Important Note

CD61 is generally interpreted together with other megakaryocytic and myeloid markers such as CD41, CD42b, CD34, CD45, CD33, CD13, CD117, and HLA-DR. Comprehensive interpretation by a hematopathologist is essential for accurate diagnosis and disease classification.